RevBio is a clinical stage company developing a regenerative, high-strength, injectable bone adhesive called Tetranite® that provides a new capability for surgeons to transform bone fixation and repair. Not only does this technology have immediate load-bearing strength, bonding bone to bone as well as bone to metal, but it also reabsorbs and is replaced with new bone during the natural bone healing process. Research indicates that the load-bearing material is also osteopromotive and accelerates bone healing and remodeling. The use of this unique material will reduce the duration and complexity of orthopedic and dental procedures, allow for more minimally invasive surgeries, and improve patient outcomes by reducing their pain, recovery time, and the overall cost of care.
RevBio is developing a portfolio of specific applications in dental, cranial, spine, and orthopaedics which address several large market opportunities. RevBio has funded its operation to date with an investment of $18 million from accredited investors and has received an additional $8.5 million from non-dilutive research grants. The Company is currently seeking to raise a $25 million Series A round from institutional investors which is projected to fund the Company through the completion of its dental clinical studies, the initiation of clinical studies for cranial flap fixation and trauma indications as well as the commercial launch of its first animal health product.